¹⁷⁷Lu-ITM-31 (¹⁷⁷Lu-LuCaFab) is a carbonic anhydrase XII-specific antibody Fab fragment. CAXII is highly expressed on the cell surface of glioblastoma cells, but not found on healthy brain cells. The radiolabeled compound is administered via intracavitary injection, meaning it is applied directly into the tumor cavity following the surgical removal of the tumor to attack residual cancerous cells that lead to recurrent disease. LuCaFab thus acts as a complementary, Adjuvant therapy to the current standard of care approach to glioblastoma as it is designed to be applied after initial treatment to prevent future tumor growth. The drug entered Phase I clinical trial in 2023.

Target/Mechanism: CAXII

Carrier/Ligand: Fab

Radiation Type: beta electrons (β^–)